Trisha Michel Wise-Draper , MD,PhD

Bachelor's Degree: Miami University 2002 (Zoology)

Doctoral Degree: University of Cincinnati 2008 (Cancer Biology)

Medical Degree: University of Cincinnati Cincinnati, OH, 2010

Residency: University of Cincinnati Cincinnati, OH, 2010 (Internal Medicine )

Fellowship: University of Cincinnati Cincinnati, OH, 2011 (Hematology/Oncology )

Residency: University of Cincinnati Medical Center 2012 (Internal Medicine)

American Board of Internal Medicine (Certification Date: 08-06-2013 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 10-27-2015 )

Hematology and Oncology

Lung Cancer

Thyroid Cancer

Adenoid Cancer

Alveolar Ridge Cancer

Bucal Cavity Cancer

Ear Cancer

Laryngeal Cancer

Mouth Cancer

Nasopharyngeal Cancer

Neck Cancer

Oral Cancer

Oropharyngeal Cancer

Parotid Gland Cancer

Pharynx Cancer

Salivary Gland Cancer

Soft Palate Cancer

Throat Cancer

Thymoma

Tongue Cancer

Tonsil Cancer

Internal Medicine

Medical Oncology

The laboratory focuses on translational mechanisms of therapeutic resistance and biomarkers in cancer. Our main model of disease is head and neck cancer (HNC) which is the 6th most common cancer worldwide.  Many treatments for HNC are toxic and result in significant morbidity. In addition, the outcomes in locally advanced HNC, especially those with high risk features and those that develop recurrence, are poor.  Therefore, using patient tissue/blood samples as well as established HNC cell lines and patient derived xenograft (PDX) models, we are attempting to identify novel targets, potential biomarkers of resistance, and new treatments to lessen toxicity and improve outcomes.
Specifically, we are interested in identifying mechanisms important for immunotherapy (anti-PD-1) resistance including T cell dysfunction, the role of macrophages and possible signaling pathways involved. We have already identified a couple of potential mediators that we plan to target in tissues from patients resistant to immunotherapy. We have also identified the DEK oncogene as a possible blood biomarker and immune cell stimulator in HNC patients.  We are now studying possible mechanisms in which DEK is secreted into the blood and its role in cancer immune surveillance and outcome. These studies are fundamental to 1) identify patients likely to respond to particular treatment modalities for personalized medicine, 2) understanding the mechanism of immune surveillance in cancer and 3) develop new therapies that can easily be translated into phase I clinical trials.

Grant: #Check 3567 Investigators:Langevin, Scott; Wise-Draper, Trisha; Zhang, Xiang 01-01-2016 -12-31-2016 Elsa U. Pardee Foundation Targeted Mutation Sequencing to Predict Definitive Chemoradiation Response for Head and Neck Cancer Role:Collaborator $168,947.00 Awarded Level:Private Non-Profit

Grant: #Gromada Investigators:Langevin, Scott; Wise-Draper, Trisha 07-01-2016 -06-30-2017 Brandon C. Gromada Head and Neck Cancer Foundation Efficacy of an LSD1 Inhibitor (GSK2879552) for Treating Sinonasal Squamous Cancer Role:Collaborator $20,000.00 Active Level:Private Non-Profit

Grant: #W81XWH-17-1-0377 (CA160714P1) Investigators:Wise-Draper, Trisha 07-01-2017 -06-30-2020 Department of the Army Medical Research Acquisition Activity Ionic mechanisms of resistance to immunotherapy in head and neck cancer Role:PI $532,944.00 Active Level:Federal

Grant: #R21DE027227 Investigators:Kasper, Susan; Langevin, Scott; Medvedovic, Mario; Wise-Draper, Trisha; Zhang, Xiang 09-01-2017 -08-31-2019 National Institute of Dental and Craniofacial Research Exosomal miRNA as Salivary Biomarkers for HPV+ Head and Neck Carcinoma Role:Collaborator $239,250.00 Awarded Level:Federal

Grant: #27469-033 Investigators:Eisenhauer, Eric; Reid, Thomas; Richards, William; Wise-Draper, Trisha 04-01-2010 -02-28-2019 National Cancer Institute Gynecologic Oncology Group Clinical Trial #27469 Role:PI $655,610.32 Active Level:Federal

Grant: #RES512929-UC / TECG20180266 Investigators:Wise-Draper, Trisha; Zender, Chad 05-15-2019 -12-31-2019 Ohio Development Services Agency Determining hBD-3 as a valid biomarker in head and neck cancer Role:Collaborator $20,000.00 Awarded Level:State of Ohio

Grant: #RSG-19-111-01-CCE Investigators:Borchers, Michael; Hinrichs, Benjamin; Wise-Draper, Trisha; Zender, Chad 01-01-2020 -12-31-2023 American Cancer Society - National Chapter Harnessing the Natural Killer Cytotoxic Response in Head and Neck Cancer Role:PI $792,000.00 Active Level:Private Non-Profit

Grant: #C-1400-01 Investigators:Wise-Draper, Trisha 10-04-2021 -10-03-2024 Agenus, Inc. A PHASE 1 STUDY INVESTIGATING AGEN1777 AS A SINGLE-AGENT AND IN COMBINATION WITH PD-1 INHIBITION IN PATIENTS WITH ADVANCED SOLID TUMORS Role:PI 0.00 Hold Level:Industry

Grant: #1U01CA267985 Investigators:Dillehay McKillip, Kelsey; Greis, Kenneth; Wise-Draper, Trisha 02-15-2022 -01-31-2027 National Cancer Institute Optimization of peripheral blood mononuclear cell (PBMC) processing for robust downstream functional immune cell analysis and correlation with therapeutic efficacy Role:PI 353556.00 Awarded Level:Federal

Grant: #C4471001 Investigators:Wise-Draper, Trisha 09-01-2021 -09-01-2024 Pfizer, Inc. A 2-part, Phase 1A/B, open-label, multicenter trial evaluating pharmacokinetics, safety & efficacy of PF-07284890 (ARRY-461) in participants with BRAF V600-MUTANT solid tumors w/,w/o brain involvement Role:PI 511506.05 Hold Level:Industry

Grant: #YL-13027-003 04-01-2022 -03-31-2025 280 Bio, Inc. A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients with Advanced Solid Tumors Role:PI 515365.39 Hold Level:Industry

Grant: #YL-13027-003 04-01-2022 -03-31-2025 280 Bio, Inc. A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients with Advanced Solid Tumors Role:PI 515365.39 Hold Level:Industry

Grant: #R61NS128232 Investigators:Desai, Pankaj; Gudelsky, Gary; Phoenix, Timothy; Plas, David; Rodenberg, Cynthia; Sengupta, Soma; Wise-Draper, Trisha 08-01-2022 -07-31-2025 National Institute of Neurological Disorders and Stroke Translational Studies to facilitate Rational Therapeutic Combinations of Letrozole for the Treatment of Glioblastoma Role:Collaborator 389244.00 Awarded Level:Federal

Grant: #2021-1306 05-01-2022 -04-30-2025 Mink Therapeutics, Inc. A PHASE 1 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) AS A SINGLE AGENT AND IN COMBINA Role:PI 385545.85 Hold Level:Industry

Grant: #2021-1306 05-01-2022 -04-30-2025 Mink Therapeutics, Inc. A PHASE 1 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) AS A SINGLE AGENT AND IN COMBINA Role:PI 385545.85 Hold Level:Industry

Grant: #UCCC-HN-21-02 Investigators:Wise-Draper, Trisha 11-01-2021 -11-01-2024 Janssen Pharmaceutica Research Foundation Phase II study to evaluate amivantamab in recurrent and metastatic adenoid cystic carcinoma Role:PI 613186.20 Hold Level:Industry

Grant: #2019-1305 05-01-2022 -04-30-2025 Mink Therapeutics, Inc. A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRAC Role:PI 527613.84 Hold Level:Industry

Grant: #2019-1305 05-01-2022 -04-30-2025 Mink Therapeutics, Inc. A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRAC Role:PI 527613.84 Hold Level:Industry

Grant: #AN2025H0301 04-01-2022 -03-31-2025 Adlai Nortye USA Inc. The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Role:PI 629416.75 Hold Level:Industry

Grant: #AN2025H0301 04-01-2022 -03-31-2025 Adlai Nortye USA Inc. The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Role:PI 629416.75 Hold Level:Industry

Grant: #IOV-GM1-201 07-01-2022 -06-30-2025 Highline Sciences A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer Role:PI 757882.93 Hold Level:Industry

Grant: #IOV-GM1-201 07-01-2022 -06-30-2025 Highline Sciences A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer Role:PI 757882.93 Hold Level:Industry

Grant: #COMMANDER-001 04-01-2022 -03-31-2025 SQZ Biotechnologies Company A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Role:PI 2734938.15 Hold Level:Industry

Grant: #COMMANDER-001 04-01-2022 -03-31-2025 SQZ Biotechnologies Company A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Role:PI 2734938.15 Hold Level:Industry

Grant: #R21CA277341 Investigators:Conforti, Laura; Khodoun, Marat; Wise-Draper, Trisha 12-09-2022 -11-30-2024 National Cancer Institute Liposome-based mRNA cancer immunotherapy targeting ion channels Role:Collaborator 189338.00 Awarded Level:Federal

Grant: #TAC01-HER2-03_4732-0003 01-12-2023 -01-28-2028 Triumvira Immunologics, Inc. A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) Role:PI 0.00 Active Level:Industry

Grant: #TAC01-HER2-03_4732-0003 01-12-2023 -01-28-2028 Triumvira Immunologics, Inc. A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2) Role:PI 0.00 Active Level:Industry

Grant: #GN-P01-001 01-12-2023 -01-29-2028 Novotech Clinical Research USA, LLC Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor Role:PI 0.00 Active Level:Industry

Grant: #GN-P01-001 01-12-2023 -01-29-2028 Novotech Clinical Research USA, LLC Phase I, Open-label study to evaluate safety, tolerability and preliminary efficacy of modified Salmonella typhimurium SGN1 in Patients with Advanced Solid Tumor Role:PI 0.00 Active Level:Industry

Grant: #YL-13027-003 01-31-2023 -12-31-2027 280 Bio, Inc. Amendment 1: A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients with Advanced Solid Tumors. Role:PI 0.00 Active Level:Industry

Grant: #YL-13027-003 01-31-2023 -12-31-2027 280 Bio, Inc. Amendment 1: A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YL-13027 in Patients with Advanced Solid Tumors. Role:PI 0.00 Active Level:Industry

Grant: #INCAGN1876-204 02-13-2023 -01-29-2028 Incyte Corporation A Phase 2, Open-Label, multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or metastatic Head and Neck Squamous Cell Carcinoma Role:PI 0.00 Active Level:Industry

Grant: #INCAGN1876-204 02-13-2023 -01-29-2028 Incyte Corporation A Phase 2, Open-Label, multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or metastatic Head and Neck Squamous Cell Carcinoma Role:PI 0.00 Active Level:Industry

-01-03-2027 Caris Pharmatech, Inc. PWA-RAIN-3202 Role:PI 0.00 Active Level:Industry

-01-03-2027 Caris Pharmatech, Inc. PWA-RAIN-3202 Role:PI 0.00 Active Level:Industry

Grant: #ERAS-601-01 -01-28-2028 Erasca, Inc. An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Role:PI 0.00 Active Level:Industry

Grant: #ERAS-601-01 -01-28-2028 Erasca, Inc. An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Role:PI 0.00 Active Level:Industry

Grant: #XmAb808-2281-0162 Investigators:Wise-Draper, Trisha 06-12-2023 -06-12-2026 Xencor, Inc A Phase 1 First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety Tolerability, Role:PI 1664361.67 Hold Level:Industry

Grant: #CA115-001 Investigators:Wise-Draper, Trisha 08-01-2023 -08-01-2026 Bristol-Myers Squibb Co. A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer Role:PI 562481.07 Hold Level:Industry

Investigators:Chaudhary, Rekha; Desai, Pankaj; Medvedovic, Mario; Plas, David; Rai, Shesh; Wise-Draper, Trisha; Zuccarello, Mario 11-30-2023 -11-30-2024 Dr. Ralph and Marian Falk Medical Research Trust Clinical and Correlative Translational Studies for Repurposing Letrozole as a Novel Therapeutic for Glioblastoma: Proof of Efficacy in Combination with Metronomic Temozolomide Role:Collaborator 211322.00 Hold Level:Non Profit

Grant: #DS1055-A-J101 Investigators:Wise-Draper, Trisha 01-16-2024 -01-16-2027 Daiichi Sankyo Company, LTD. A PHASE 1, FIRST IN HUMAN STUDY OF DS-1055A IN SUBJECTS WITH RELAPSED OR REFRACTORY LOCALLY ADVANCED OR METASTATIC SOLID TUMORS Role:PI 551034.45 Hold Level:Industry

Grant: #DB-1311-O-1001 Investigators:Wise-Draper, Trisha 02-21-2024 -02-21-2027 DualityBio Inc. A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic So Role:PI 0.00 Hold Level:Industry

Grant: #RP3-002 Investigators:Wise-Draper, Trisha 02-22-2024 -02-22-2027 Replimune, Inc. Replimune, Inc. RP3-002 Reimbursement Role:PI 20750.00 Active Level:Industry

Grant: #SRF114-101 Investigators:Wise-Draper, Trisha 08-19-2024 -08-19-2027 Coherus Biosciences, Inc A PHASE 1 STUDY OF CHS-114 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS Role:PI 0.00 Hold Level:Industry

Grant: #CHS-007-01 / RTOG 3521 Investigators:Wise-Draper, Trisha 10-07-2024 -10-07-2027 Coherus Biosciences, Inc TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Native Participants Role:PI 94369.03 Hold Level:Industry

Grant: #IDE196-001 Investigators:Wise-Draper, Trisha 10-21-2024 -10-21-2027 Ideaya Biosciences, Inc. A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11mutations or PRKC fusions Role:PI 0.00 Hold Level:Industry

Published Abstracts

Pease, N.A., Wise-Draper, T. and Privette Vinnedge, L. (2015. ) Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer .[Abstract]Journal of oncology,

Adams, A.K., Hallenbeck, G.E., Casper, K.A., Patil, Y.J., Wilson, K.M., Kimple, R.J., Lambert, P.F., Witte, D.P., Xiao, W., Gillison, M.L., Wise-Draper T.M., and Wikenheiser-Brokamp, K.A. (2015. ) DEK promotes HPV-positive and-negative head and neck cancer cell proliferation .[Abstract]Oncogene, 34(7) ,868

Wise-Draper, T.M., Mintz-Cole, R.A., Morris, T.A., Simpson, D.S., Wikenheiser-Brokamp, K.A., Currier, M.A., Cripe, T.P., Grosveld, G.C. and Wells, S.I. (2009. ) Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo .[Abstract]Cancer research, 69(5) ,1792

Peer Reviewed Publications

Riaz, Muhammad Kashif; Bal, Susan; Wise-Draper, Trisha (2016. ) The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.Journal of surgical oncology, , More Information

Adams, A K; Hallenbeck, G E; Casper, K A; Patil, Y J; Wilson, K M; Kimple, R J; Lambert, P F; Witte, D P; Xiao, W; Gillison, M L; Wikenheiser-Brokamp, K A; Wise-Draper, T M; Wells, S I (2015. ) DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.Oncogene, , 34 (7 ) ,868-77 More Information

Pease, Nicholas A; Wise-Draper, Trisha; Privette Vinnedge, Lisa (2015. ) Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.Journal of oncology, , 2015 ,106517 More Information

Ghose, Abhimanyu; Yellu, Mahender; Wise-Draper, Trisha; Sharma, Divya; Qualtieri, Julianne; Latif, Tahir; Medlin, Stephen (2014. ) Lymphoma presenting as secondary HLH: a review with a tale of two cases.Clinical lymphoma, myeloma & leukemia, , 14 (6 ) ,e187-93 More Information

Adams, Allie K; Wise-Draper, Trisha M; Wells, Susanne I (2014. ) Human papillomavirus induced transformation in cervical and head and neck cancers.Cancers, , 6 (3 ) ,1793-820 More Information

Bahassi, El Mustapha; Li, Ya-Qin; Wise-Draper, Trisha M; Deng, Li; Wang, Jiang; Darnell, Colleen N; Wilson, Keith M; Wells, Susanne I; Stambrook, Peter J; Rixe, Olivier (2013. ) A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.European journal of cancer (Oxford, England : 1990), , 49 (10 ) ,2345-55 More Information

Wise-Draper, Trisha M; Draper, David J; Gutkind, J Silvio; Molinolo, Alfredo A; Wikenheiser-Brokamp, Kathryn A; Wells, Susanne I (2012. ) Future directions and treatment strategies for head and neck squamous cell carcinomas.Translational research : the journal of laboratory and clinical medicine, , 160 (3 ) ,167-77 More Information

Kavanaugh, Gina M; Wise-Draper, Trisha M; Morreale, Richard J; Morrison, Monique A; Gole, Boris; Schwemberger, Sandy; Tichy, Elisia D; Lu, Lu; Babcock, George F; Wells, James M; Drissi, Rachid; Bissler, John J; Stambrook, Peter J; Andreassen, Paul R; Wiesmüller, Lisa; Wells, Susanne I (2011. ) The human DEK oncogene regulates DNA damage response signaling and repair.Nucleic acids research, , 39 (17 ) ,7465-76 More Information

Wise-Draper, Trisha M; Mintz-Cole, Rachael A; Morris, Teresa A; Simpson, David S; Wikenheiser-Brokamp, Kathryn A; Currier, Mark A; Cripe, Timothy P; Grosveld, Gerard C; Wells, Susanne I (2009. ) Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.Cancer research, , 69 (5 ) ,1792-9 More Information

Wise-Draper, Trisha M; Morreale, Richard J; Morris, Teresa A; Mintz-Cole, Rachael A; Hoskins, Elizabeth E; Balsitis, Scott J; Husseinzadeh, Nader; Witte, David P; Wikenheiser-Brokamp, Kathryn A; Lambert, Paul F; Wells, Susanne I (2009. ) DEK proto-oncogene expression interferes with the normal epithelial differentiation program.The American journal of pathology, , 174 (1 ) ,71-81 More Information

Hoskins, E E; Gunawardena, R W; Habash, K B; Wise-Draper, T M; Jansen, M; Knudsen, E S; Wells, S I (2008. ) Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.Oncogene, , 27 (35 ) ,4798-808 More Information

Wise-Draper, Trisha M; Wells, Susanne I (2008. ) Papillomavirus E6 and E7 proteins and their cellular targets. Frontiers in bioscience : a journal and virtual library, , 13 ,1003-17

Wise-Draper, Trisha M; Allen, Hillary V; Jones, Elizabeth E; Habash, Kristen B; Matsuo, Hiroshi; Wells, Susanne I (2006. ) Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.Molecular and cellular biology, , 26 (20 ) ,7506-19 More Information

Wise-Draper, Trisha M; Allen, Hillary V; Thobe, Megan N; Jones, Elizabeth E; Habash, Kristen B; Münger, Karl; Wells, Susanne I (2005. ) The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.Journal of virology, , 79 (22 ) ,14309-17 More Information

Wise-Draper, Trisha M; Moorthy, Ganesh; Salkeni, Mohamad A; Karim, Nagla Abdel; Thomas, Hala Elnakat; Mercer, Carol A; Beg, M Shalaan; O'Gara, Sue; Olowokure, Olugbenga; Fathallah, Hassana; Kozma, Sara C; Thomas, George; Rixe, Olivier; Desai, Pankaj; Morris, John C (2017. ) A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.Targeted oncology, , 12 (3 ) ,323-332 More Information

Chimote, Ameet A; Hajdu, Peter; Sfyris, Alexandros M; Gleich, Brittany N; Wise-Draper, Trisha; Casper, Keith A; Conforti, Laura (2017. ) Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.Cancer research, , 77 (1 ) ,53-61 More Information

Malhotra, Akshiv; Sendilnathan, Arun; Old, Matthew O; Wise-Draper, Trisha M (2015. ) Oncolytic virotherapy for head and neck cancer: current research and future developments.Oncolytic virotherapy, , 4 ,83-93 More Information

Tsurutani, Junji; Iwata, Hiroji; Krop, Ian; Jänne, Pasi A; Doi, Toshihiko; Takahashi, Shunji; Park, Haeseong; Redfern, Charles; Tamura, Kenji; Wise-Draper, Trisha M; Saito, Kaku; Sugihara, Masahiro; Singh, Jasmeet; Jikoh, Takahiro; Gallant, Gilles; Li, Bob T (2020. ) Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.Cancer discovery, , More Information

Agresta, Laura; Lehn, Maria; Lampe, Kristin; Cantrell, Rachel; Hennies, Cassandra; Szabo, Sara; Wise-Draper, Trisha; Conforti, Laura; Hoebe, Kasper; Janssen, Edith M (2020. ) CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.Journal for immunotherapy of cancer, , 8 (1 ) , More Information

Chimote, Ameet A; Gawali, Vaibhavkumar S; Newton, Hannah S; Wise-Draper, Trisha M; Conforti, Laura (2020. ) A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8+ T Cells in Head and Neck Cancer.Frontiers in pharmacology, , 11 ,143 More Information

Gulati, Shuchi; Desai, Janki; Palackdharry, Sarah M; Morris, John C; Zhu, Zheng; Jandarov, Roman; Riaz, Muhammad K; Takiar, Vinita; Mierzwa, Michelle; Gutkind, J Silvio; Molinolo, Alfredo; Desai, Pankaj B; Sadraei, Nooshin Hashemi; Wise-Draper, Trisha M (2020. ) Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.Cancer, , 126 (2 ) ,354-362 More Information

Ribrag, Vincent; Avigan, David E; Green, Damian J; Wise-Draper, Trisha; Posada, Juan G; Vij, Ravi; Zhu, Ying; Farooqui, Mohammed Z H; Marinello, Patricia; Siegel, David S (2019. ) Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.British journal of haematology, , 186 (3 ) ,e41-e44 More Information

Kofuji, Satoshi; Hirayama, Akiyoshi; Eberhardt, Alexander Otto; Kawaguchi, Risa; Sugiura, Yuki; Sampetrean, Oltea; Ikeda, Yoshiki; Warren, Mikako; Sakamoto, Naoya; Kitahara, Shuji; Yoshino, Hirofumi; Yamashita, Daisuke; Sumita, Kazutaka; Wolfe, Kara; Lange, Lisa; Ikeda, Satsuki; Shimada, Hiroko; Minami, Noriaki; Malhotra, Akshiv; Morioka, Shin; Ban, Yuki; Asano, Maya; Flanary, Victoria L; Ramkissoon, Annmarie; Chow, Lionel M L; Kiyokawa, Juri; Mashimo, Tomoyuki; Lucey, Greg; Mareninov, Sergey; Ozawa, Tatsuya; Onishi, Nobuyuki; Okumura, Koichi; Terakawa, Jumpei; Daikoku, Takiko; Wise-Draper, Trisha; Majd, Nazanin; Kofuji, Kaori; Sasaki, Mika; Mori, Masaru; Kanemura, Yonehiro; Smith, Eric P; Anastasiou, Dimitrios; Wakimoto, Hiroaki; Holland, Eric C; Yong, William H; Horbinski, Craig; Nakano, Ichiro; DeBerardinis, Ralph J; Bachoo, Robert M; Mischel, Paul S; Yasui, Wataru; Suematsu, Makoto; Saya, Hideyuki; Soga, Tomoyoshi; Grummt, Ingrid; Bierhoff, Holger; Sasaki, Atsuo T (2019. ) IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.Nature cell biology, , 21 (8 ) ,1003-1014 More Information

Haque, Sulsal; Karivedu, Vidhya; Riaz, Muhammed K; Choi, David; Roof, Logan; Hassan, Sarah Z; Zhu, Zheng; Jandarov, Roman; Takiar, Vinita; Tang, Alice; Wise-Draper, Trisha (2019. ) High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.Oral oncology, , 88 ,9-15 More Information

Haque, Sulsal-Ul; Niu, Liang; Kuhnell, Damaris; Hendershot, Jacob; Biesiada, Jacek; Niu, Wen; Hagan, Matthew C; Kelsey, Karl T; Casper, Keith A; Wise-Draper, Trisha M; Medvedovic, Mario; Langevin, Scott M (2018. ) Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma.Head & neck, , 40 (7 ) ,1555-1564 More Information

Chimote, Ameet A; Balajthy, Andras; Arnold, Michael J; Newton, Hannah S; Hajdu, Peter; Qualtieri, Julianne; Wise-Draper, Trisha; Conforti, Laura (2018. ) A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.Science signaling, , 11 (527 ) , More Information

Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa (2018. ) Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.Translational oncology, , 11 (1 ) ,168-174 More Information

Langevin, Scott; Kuhnell, Damaris; Parry, Tess; Biesiada, Jacek; Huang, Shouxiong; Wise-Draper, Trisha; Casper, Keith; Zhang, Xiang; Medvedovic, Mario; Kasper, Susan (2017. ) Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro reveals common secretion profiles and potential utility as salivary biomarkers.Oncotarget, , 8 (47 ) ,82459-82474 More Information

Old, Matthew O; Wise-Draper, Trisha; Wright, Chadwick L; Kaur, Balveen; Teknos, Theodoros (2016. ) The current status of oncolytic viral therapy for head and neck cancer.World journal of otorhinolaryngology - head and neck surgery, , 2 (2 ) ,84-89 More Information

Chimote A.A.;Gawali V.S.;Newton H.S.;Wise-Draper T.M.;Conforti L. (02-28-2020. ) A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabi.Frontiers in Pharmacology, , 11 , More Information

Brana I.; Cohen E.E.W.; Cook C.E.; Harrington K.J.; Hong D.S.; Keilholz U.; McCoon P.; Mehta M.; Mesia R.; Mitchell P.D.; Mugundu G.M.; Perez Segura P.; Scott M.L.; Wise-Draper T. (10-01-2018. ) A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in .Annals of oncology : official journal of the European Society for Medical Oncology, , 29 ,viii372 More Information

Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. (01-01-2018. ) Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in.Translational Oncology, , 11 (1 ) ,168-174 More Information

Langevin S.;Kuhnell D.;Parry T.;Biesiada J.;Huang S.;Wise-Draper T.;Casper K.;Zhang X.;Medvedovic M.;Kasper S. (01-01-2017. ) Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro re.Oncotarget, , 8 (47 ) ,82459-82474 More Information

Pease N.;Wise-Draper T.;Privette Vinnedge L. (01-01-2015. ) Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.Journal of Oncology, , 2015 , More Information

Adams A.;Wise-Draper T.;Wells S. (09-15-2014. ) Human papillomavirus induced transformation in cervical and head and neck cancers.Cancers, , 6 (3 ) ,1793-1820 More Information

Wise-Draper T.M.;Draper D.J.;Gutkind J.S.;Molinolo A.A.;Wikenheiser-Brokamp K.A.;Wells S.I. (01-01-2012. ) Future directions and treatment strategies for head and neck squamous cell carcinomas.Translational Research, , 160 (3 ) ,167-177 More Information

Wise-Draper T.;Wells S. (03-01-2005. ) Efficient transfection of siRNA against HPV oncogenes .BioSpektrum, , 11 (1 ) ,107-108

Wells S.;Aronow B.;Wise T.;Williams S.;Couget J.;Howley P. (06-10-2003. ) Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer .Proceedings of the National Academy of Sciences of the United States of America, , 100 (12 ) ,7093-7098 More Information

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2158
Fax: 513-558-2124
trisha.wise@uc.edu